Silence Therapeutics vs Spruce Biosciences
SLN and SPRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLN and SPRB compare
Silence Therapeutics scores higher on the StockData Score (6 against 3 for Spruce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLN | SPRB |
|---|---|---|
| Size and price | ||
| Market cap | – | $124M |
| Share price | $19.83 | $43.31 |
| Change, 1 year | 195% | −57.6% |
| Change, 5 years | −13.6% | −80.3% |
| Beta (5Y) | 1.05 | – |
| Employees | 88 | 8 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.9× |
| Growth | ||
| Revenue growth (TTM) | −97.7% | – |
| Profitability | ||
| Gross margin | 85.9% | – |
| Operating margin | −11107% | – |
| Net margin | −9748% | – |
| FCF margin | −6873% | – |
| Return on equity | −90.4% (better) | −187% |
| Financial health | ||
| Debt / equity | 0.00 | 0.12 (better) |
| Interest coverage | – | −21.3× |
| Current ratio | 7.42 (better) | 4.83 |
| Altman Z-score | – | −3.64 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 16.6% | 69.7% |
| Held by insiders | 48.1% | 71.7% |
| Short interest, % of float | – | 65.3% |
Go deeper
- SLN stock overview
- SLN income statement
- SLN valuation and score
- SPRB stock overview
- SPRB income statement
- SPRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.